Retraction Casts Doubt on Timing Effects of Immunotherapy.

A discredited trial has fractured trust in one landmark result-the first randomized evidence on checkpoint inhibitor dosing timing-but not the broader hypothesis it was meant to prove: that circadian biology shapes immunotherapy efficacy. Researchers on both sides of the debate are now recalculating what the surviving evidence can actually support.